Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;15(11):1255-70.
doi: 10.1586/14737175.2015.1101346. Epub 2015 Oct 15.

Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review

Omar Abdel-Rahman  1 , Mona Fouad  2
Affiliations

Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review

Omar Abdel-Rahman et al. Expert Rev Neurother. 2015.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Expert Rev Neurother. 2016;16(1):103. doi: 10.1586/14737175.2016.1126039. Epub 2015 Dec 15. Expert Rev Neurother. 2016. PMID: 26666507 No abstract available.

Abstract

This systematic review aims to assess irinotecan-based salvage regimens for patients with recurrent glioblastoma multiforme (GBM) beyond first line treatment. Eligible trials were identified using databases search and 25 studies were included in the final analysis. Among the 25 studies, PFS-6 rate was reported in 15 studies and it ranged from 16% to 63%. Median PFS was reported in 18 studies and it ranged from 1 to 7.6 months. While for median OS, it was reported in 17 studies and it ranged from 5.8 months to 17.9 months. The available data suggests that routine use of irinotecan-based salvage regimens cannot be recommended outside the setting of well-controlled prospective randomized studies investigating novel combinations of irinotecan.

Keywords: GBM; irinotecan; salvage treatment; second line; systemic treatment.

PubMed Disclaimer

Publication types

LinkOut - more resources